Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
IL-34 is a Treg-specific cytokine and mediates transplant tolerance
Séverine Bézie, … , Ignacio Anegon, Carole Guillonneau
Séverine Bézie, … , Ignacio Anegon, Carole Guillonneau
Published September 21, 2015
Citation Information: J Clin Invest. 2015;125(10):3952-3964. https://doi.org/10.1172/JCI81227.
View: Text | PDF
Research Article

IL-34 is a Treg-specific cytokine and mediates transplant tolerance

  • Text
  • PDF
Abstract

Cytokines and metabolic pathway–controlling enzymes regulate immune responses and have potential as powerful tools to mediate immune tolerance. Blockade of the interaction between CD40 and CD40L induces long-term cardiac allograft survival in rats through a CD8+CD45RClo Treg potentiation. Here, we have shown that the cytokine IL-34, the immunoregulatory properties of which have not been previously studied in transplantation or T cell biology, is expressed by rodent CD8+CD45RClo Tregs and human FOXP3+CD45RCloCD8+ and CD4+ Tregs. IL-34 was involved in the suppressive function of both CD8+ and CD4+ Tregs and markedly inhibited alloreactive immune responses. Additionally, in a rat cardiac allograft model, IL-34 potently induced transplant tolerance that was associated with a total inhibition of alloantibody production. Treatment of rats with IL-34 promoted allograft tolerance that was mediated by induction of CD8+ and CD4+ Tregs. Moreover, these Tregs were capable of serial tolerance induction through modulation of macrophages that migrate early to the graft. Finally, we demonstrated that human macrophages cultured in the presence of IL-34 greatly expanded CD8+ and CD4+ FOXP3+ Tregs, with a superior suppressive potential of antidonor immune responses compared with non–IL-34–expanded Tregs. In conclusion, we reveal that IL-34 serves as a suppressive Treg–specific cytokine and as a tolerogenic cytokine that efficiently inhibits alloreactive immune responses and mediates transplant tolerance.

Authors

Séverine Bézie, Elodie Picarda, Jason Ossart, Laurent Tesson, Claire Usal, Karine Renaudin, Ignacio Anegon, Carole Guillonneau

×

Figure 8

Efficient human FOXP3+ Treg expansion and potentiation following IL-34–induced macrophage differentiation.

Options: View larger image (or click on image) Download as PowerPoint
Efficient human FOXP3+ Treg expansion and potentiation following IL-34–i...
CD14+ monocytes were differentiated for 6 days with IL-34 or not and added to total allogeneic PBMCs for 21 days. The percentage of FOXP3+ cells was evaluated in PBMCs among CD4+ or CD8+ CD45RClo or CD45RChi T cells. A representative plot (A) and graph (B) are shown before and after culture for 3 healthy individuals. Mϕ, macrophages. (C) Fold expansion was evaluated for FOXP3+ CD4+ or CD8+ Tregs. (D) Unstimulated, stimulated, or IL-34–expanded CD4+CD25hiCD127lo and CD8+CD45RClo Tregs were tested for suppression of CFSE-labeled CD4+CD25– T cell proliferation in response to allogeneic T cell–depleted PBMCs and analyzed by flow cytometry for CFSE dilution after 5 days of culture (n = 3). The proportion of dividing CD4+CD25– T cells in the control proliferation condition with allogeneic T cell–depleted PBMCs only represented approximately 60% of the cells on day 5 and was given a value of 100 in each experiment. Results are expressed as the mean ± SEM of the relative proportion of dividing CD4+CD25– T cells. A representative raw CFSE profile is shown. Two-way repeated-measures ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts